AbbVie (NYSE:ABBV) Shares Down 1.7% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV) was down 1.7% during mid-day trading on Wednesday . The stock traded as low as $226.07 and last traded at $228.7910. Approximately 5,478,190 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 7,577,379 shares. The stock had previously closed at $232.86.

Analyst Ratings Changes

A number of equities analysts have issued reports on ABBV shares. UBS Group lowered their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Piper Sandler raised their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $251.56.

AbbVie Price Performance

The firm’s fifty day moving average price is $223.93 and its two-hundred day moving average price is $221.63. The stock has a market cap of $404.36 billion, a price-to-earnings ratio of 96.95, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the company earned $2.16 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

Institutional Investors Weigh In On AbbVie

Several institutional investors have recently made changes to their positions in ABBV. Evolution Wealth Management Inc. purchased a new position in AbbVie in the 2nd quarter worth $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter worth $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the 2nd quarter valued at about $28,000. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the 4th quarter valued at approximately $28,000. Finally, Westend Capital Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.